Dr. Dianwen Ju received a Ph.D. degree in Medical Immunology in 1999, a Master’s degree in Pharmacology in 1994, and a Bachelor’s degree in Pharmacy in 1991 in Second Military Medical University. He is currently a Professor and Director of Microbiological & Biochemical Pharmacy in Fudan University School of Pharmacy. He has more than100 publications in peer-reviewed international journals including Journal of Clinical Oncology, Cancer Research, Autophagy, Biomaterials et al. He has invented 30 biotechnologies and leaded the R&D of 2 novel therapeutic antibodies and 2 biosimilar biologics, which are either on the market or in clinical trials. He joined Shanghai MediPharm Biotech Co. Ltd in 2002 as a director of R&D. Before joining MediPharm in 2002, Dr. Ju had been an assistant Director and a senior scientist in Shanghai Brilliance Biotech Institute and a lecturer in Immunology in Second Military Medical University.
Cancer Immunotherapy; Antibody-based Therapeutics; Recombinant Therapeutic Biologics; Gene Therapy and Cell Therapy
Dr. Dian-Wen Ju received a Ph.D. degree in Medical Immunology in 1999, a Master’s degree in Pharmacology in 1994, and a Bachelor’s degree in Pharmacy in 1991 in Second Military Medical University.
He is currently a Professor and Director of Microbiological & Biochemical Pharmacy in Fudan University School of Pharmacy. He has more than 110 publications in peer-reviewed international journals including Journal of Clinical Oncology, Cancer Research, Autophagy, Biomaterials, Cancer Immunology Research, Frontiers in Immunology et al. He has invented 40 biotechnologies and he has leaded the R&D of 2 novel therapeutic antibodies and 2 biosimilar biologics, which are either on the market or in clinical trials.
He joined MediPharm Biotech in 2002 as a director of R&D and chief scientist. Before joining MediPharm, Dr. Ju had been an assistant Director in Shanghai Brilliance Biotech Institute and a senior scientist in the Second Military Medical University since 1999.
Selected publications
1.Zhang X, Luan J, Chen W, Fan J, Nan Y, Wang Y, Liang Y, Meng G, Ju D*. Mesoporous silica nanoparticles induced hepatotoxicity via NLRP3 inflammasome activation and caspase-1-dependent pyroptosis. Nanoscale. 2018 May 3. doi: 10.1039/c8nr00554k.
2.Luan J, Zhang X, Wang S, Li Y, Fan J, Chen W, Zai W, Wang S, Wang Y, Chen M, Meng G, Ju D*. NOD-Like Receptor Protein 3 Inflammasome-Dependent IL-1β Accelerated ConA-Induced Hepatitis. Front Immunol. 2018 Apr 10;9:758. doi: 10.3389/fimmu.2018.00758.
3.Chen W, Zhang X, Fan J, Zai W, Luan J, Li Y, Wang S, Chen Q, Wang Y, Liang Y, Ju D*. Liver-targeted therapy of acetaminophen-induced acute liver injury by interleukin-22 tethered to apolipoprotein A-I. Theranostics. 2017; 7(17):4135-4148
4.Zhang X, Fan J, Wang S, Li Y, Wang Y, Li S, Luan J, Wang Z, Song P, Chen Q, Tian W, Ju D*. Targeting CD47 and autophagy enhanced anti-tumor effects in non-small cell lung cancer. Cancer Immunology Research. 2017;5(5):363-375
5.Fan J, Sun Y, Wang S, Li Y, Zeng X, Cao Z, Yang P, Song P, Wang Z, Xian Z, Gao H, Chen Q, Cui D, Ju D*. Inhibition of autophagy overcomes the nanotoxicity elicited by Cadmium-based Quantum Dots. Biomaterials 2016;78:102-114
6.Zeng X, Zhao H, Li Y, Fan J, Sun Y, Wang Z, Wang S, Song P, Ju D*. Targeting hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL positive chronic myeloid leukemia. Autophagy. 2015, 11(2):355-372.
7.Li Y, Zhu H, Wang S, Qian X, Fan J, Wang Z, Song P, Zhang X, Lu W, Ju D*. Interplay of Oxidative Stress and Autophagy in PAMAM Dendrimers-Induced Neuronal Cell Death. Theranostics.2015; 5(12): 1363-1377.
8.Li Y, Zeng X, Wang S, Sun Y, Wang Z, Fan J, Song P, Ju D*. Inhibition of autophagy protects against PAMAM dendrimers-induced hepatotoxicity. Nanotoxicology. 2015;9(3):344-355
9.Wang S, Li Y, Fan J, Wang Z, Zeng X, Sun Y, Song P, Ju D*. The role of autophagy in the neurotoxicity of cationic PAMAM dendrimers. Biomaterials. 2014;35(26):7588-7597.
10.Liu Y, Sun Y, Cao C, Yang Y, Wu Y, Ju D*, Li F*. Long-term biodistribution in vivo and toxicity of radioactive/magnetic hydroxyapatite nanorods. Biomaterials 2014;35(10):3348-55.
11.Chen S, Yu L, Jiang C, Zhao Y, Sun D, Li S, Liao G, Chen Y, Fu Q, Tao Q, Ye D, Hu P, Khawli LA, Taylor CR, Epstein AL, Ju DW*. Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. J Clin Oncol. 2005;23(7):1538-1547.
12.Ju DW, Yang Y, Lou GL, Tao Q, He L, Cao X*. Interleukin 18 transfection enhances anti-tumor immunity induced by dendritic cell-tumor cell conjugates. Cancer Research, 2001;61(9):3735-3740.
